-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On November 1, news, pharmaceutical giant AstraZeneca announced that it has transferred the global rights of Eklira and Duaklir, two respiratory drugs, to Covis Pharma
.
According to the agreement, Covis Pharma will pay AstraZeneca US$270 million after the transaction is completed, and at the same time bear the subsequent development costs of the drug
.
The transaction is expected to be completed in the fourth quarter of 2021
.
Public information shows that Eklira (Aclidinium Bromide) and Duaklir (Aclidinium Bromide/Formoterol) were developed by Almirall and are both used to treat patients with chronic obstructive pulmonary disease (COPD)
.
AstraZeneca obtained the global rights to these two products from Almirall in July 2014
.
Chronic obstructive pulmonary disease is a chronic persistent pulmonary disease, which is characterized by persistent airflow limitation, which causes serious irreversible damage to the patient's respiratory system and greatly reduces the patient's quality of life
.
Eklira was developed by Almirall in cooperation with Forest Laboratories.
Its active ingredient-the long-acting muscarinic antagonist (LAMA) aclidinium bromide is administered through a breath-driven inhaler Pressair twice a day
.
Moreover, Eklira will not increase the major adverse cardiovascular events of COPD patients, and can reduce the hospitalization rate of patients due to COPD aggravation
.
The product was approved for listing in the European Union and the United States in 2012
.
Duaklir is a fixed-dose compound drug composed of two long-acting bronchodilators, aclidinium bromide and formoterol fumarate, of which formoterol fumarate is a long-acting β2 receptor agonist (LABA )
.
Duaklir is administered via a dry powder inhaler Genuair twice a day.
The product was launched in the European Union in 2014 and was subsequently approved for marketing in the United States in 2019
.
Relevant data shows that Eklira and Duaklir have created a total of 1.
032 billion U.
S.
dollars in revenue from 2015 to 2019, but the total annual sales of these two products have declined in recent years.
.
In 2020, sales of Eklira and Duaklir will reach 143 million U.
S.
dollars
.
It is worth mentioning that Covis Pharma is already a "frequent customer" in the acquisition of AstraZeneca's respiratory drugs
.
Previously, in November 2018, Covis Pharma combined AstraZeneca’s three respiratory drugs Alvesco (ciclesonide inhalation aerosol), Omniris (ciclesonide nasal spray) and Zetonna (ciclesonide nasal spray).
Using aerosol) in the bag, the transaction amount exceeds 350 million US dollars
.
In recent years, the speed of AstraZeneca's divestiture of related products is accelerating
.
For example, in December 2019, Alicecam sold the commercial rights of the antipsychotic drugs Seroquel (quetiapine fumarate sustained release agent) and Seroquel XR (quetiapine fumarate sustained release agent) in Europe and Russia To the German company Cheplepharm
.
Subsequently, AstraZeneca sold the rights of breast cancer treatment Arimidex and prostate cancer treatment Casodex in Europe, the United States and other countries to the French pharmaceutical company Juvisé; in October 2020, AstraZeneca sold Atacand (candesartan) The commercial rights of Atacand Plus (candesartan medoxomil hydrochlorothiazide tablets) in about 70 countries outside the United States, China and Japan were sold to the German company Cheplapharm; in December 2020, AstraZeneca sold Crestor (rosuvastatin) And related drugs sold to Grünenthal in more than 30 European countries except Spain and the United Kingdom
.
In addition to divesting the commercial and R&D business of traditional drugs to focus on innovative drug R&D, AstraZeneca is also actively deploying the rare disease drug market
.
In 2015, AstraZeneca spent US$4 billion to acquire a 55% stake in Acerta Pharma BV.
The latter’s product line includes the blockbuster product Acalabutinib; in December 2020, AstraZeneca announced the acquisition for US$39 billion.
Alexion Pharmaceuticals, a company focused on the research and development of rare disease drugs; In September 2021, AstraZeneca announced the establishment of a rare disease business unit, officially entering the field of rare diseases
.
.
According to the agreement, Covis Pharma will pay AstraZeneca US$270 million after the transaction is completed, and at the same time bear the subsequent development costs of the drug
.
The transaction is expected to be completed in the fourth quarter of 2021
.
Public information shows that Eklira (Aclidinium Bromide) and Duaklir (Aclidinium Bromide/Formoterol) were developed by Almirall and are both used to treat patients with chronic obstructive pulmonary disease (COPD)
.
AstraZeneca obtained the global rights to these two products from Almirall in July 2014
.
Chronic obstructive pulmonary disease is a chronic persistent pulmonary disease, which is characterized by persistent airflow limitation, which causes serious irreversible damage to the patient's respiratory system and greatly reduces the patient's quality of life
.
Eklira was developed by Almirall in cooperation with Forest Laboratories.
Its active ingredient-the long-acting muscarinic antagonist (LAMA) aclidinium bromide is administered through a breath-driven inhaler Pressair twice a day
.
Moreover, Eklira will not increase the major adverse cardiovascular events of COPD patients, and can reduce the hospitalization rate of patients due to COPD aggravation
.
The product was approved for listing in the European Union and the United States in 2012
.
Duaklir is a fixed-dose compound drug composed of two long-acting bronchodilators, aclidinium bromide and formoterol fumarate, of which formoterol fumarate is a long-acting β2 receptor agonist (LABA )
.
Duaklir is administered via a dry powder inhaler Genuair twice a day.
The product was launched in the European Union in 2014 and was subsequently approved for marketing in the United States in 2019
.
Relevant data shows that Eklira and Duaklir have created a total of 1.
032 billion U.
S.
dollars in revenue from 2015 to 2019, but the total annual sales of these two products have declined in recent years.
.
In 2020, sales of Eklira and Duaklir will reach 143 million U.
S.
dollars
.
It is worth mentioning that Covis Pharma is already a "frequent customer" in the acquisition of AstraZeneca's respiratory drugs
.
Previously, in November 2018, Covis Pharma combined AstraZeneca’s three respiratory drugs Alvesco (ciclesonide inhalation aerosol), Omniris (ciclesonide nasal spray) and Zetonna (ciclesonide nasal spray).
Using aerosol) in the bag, the transaction amount exceeds 350 million US dollars
.
In recent years, the speed of AstraZeneca's divestiture of related products is accelerating
.
For example, in December 2019, Alicecam sold the commercial rights of the antipsychotic drugs Seroquel (quetiapine fumarate sustained release agent) and Seroquel XR (quetiapine fumarate sustained release agent) in Europe and Russia To the German company Cheplepharm
.
Subsequently, AstraZeneca sold the rights of breast cancer treatment Arimidex and prostate cancer treatment Casodex in Europe, the United States and other countries to the French pharmaceutical company Juvisé; in October 2020, AstraZeneca sold Atacand (candesartan) The commercial rights of Atacand Plus (candesartan medoxomil hydrochlorothiazide tablets) in about 70 countries outside the United States, China and Japan were sold to the German company Cheplapharm; in December 2020, AstraZeneca sold Crestor (rosuvastatin) And related drugs sold to Grünenthal in more than 30 European countries except Spain and the United Kingdom
.
In addition to divesting the commercial and R&D business of traditional drugs to focus on innovative drug R&D, AstraZeneca is also actively deploying the rare disease drug market
.
In 2015, AstraZeneca spent US$4 billion to acquire a 55% stake in Acerta Pharma BV.
The latter’s product line includes the blockbuster product Acalabutinib; in December 2020, AstraZeneca announced the acquisition for US$39 billion.
Alexion Pharmaceuticals, a company focused on the research and development of rare disease drugs; In September 2021, AstraZeneca announced the establishment of a rare disease business unit, officially entering the field of rare diseases
.
